HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tatsumi Matsumoto Selected Research

ozenoxacin

1/2020Anti-inflammatory effects of ozenoxacin, a topical quinolone antimicrobial agent.
6/2017Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
10/2016In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
8/2016Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tatsumi Matsumoto Research Topics

Disease

4Acne Vulgaris
01/2020 - 06/2016
3Dermatitis
02/2020 - 01/2016
2Alopecia Areata
01/2022 - 10/2021
2Contact Dermatitis (Eczema, Contact)
02/2020 - 04/2015
2Inflammation (Inflammations)
02/2020 - 04/2015
1Disease Progression
10/2021
1Skin Diseases (Skin Disease)
07/2021
1Alopecia (Baldness)
06/2021
1Postherpetic Neuralgia
04/2020
1Herpes Simplex
04/2020
1Pain (Aches)
04/2020
1Mycoses (Diseases, Fungus)
02/2020
1Irritant Dermatitis
02/2020
1Tinea Pedis (Athlete's Foot)
02/2020
1Hypersensitivity (Allergy)
01/2018
1Atopic Dermatitis (Atopic Eczema)
01/2018
1Pruritus (Itching)
01/2017
1Infections
10/2016
1Hyperplasia
01/2016
1Seizures (Absence Seizure)
02/2014
1Hyperalgesia
02/2014
1Wounds and Injuries (Trauma)
10/2010
1Lung Injury
10/2010
1Acute Lung Injury
10/2010
1Pneumonia (Pneumonitis)
10/2010
1Sepsis (Septicemia)
05/2009
1Chronic Obstructive Pulmonary Disease (COPD)
01/2007
1Lung Neoplasms (Lung Cancer)
01/2007

Drug/Important Bio-Agent (IBA)

4ozenoxacinIBA
01/2020 - 08/2016
3QuinolonesIBA
01/2020 - 10/2016
3Peptide Hydrolases (Proteases)FDA Link
01/2018 - 01/2007
2Therapeutic UsesIBA
07/2021 - 01/2020
2Messenger RNA (mRNA)IBA
06/2021 - 01/2007
2InterferonsIBA
06/2021 - 02/2020
2latoconazole (lanoconazole)IBA
02/2020 - 04/2015
2ChemokinesIBA
02/2020 - 01/2007
2Antifungal AgentsIBA
02/2020 - 04/2015
2Ointments (Pastes)IBA
01/2018 - 01/2016
2Anti-Infective Agents (Microbicides)IBA
10/2016 - 08/2016
2CytokinesIBA
01/2016 - 01/2007
2ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA
10/2010 - 05/2009
1InflammasomesIBA
01/2022
1AntibodiesIBA
10/2021
1AutoantigensIBA
10/2021
1Monophenol Monooxygenase (Tyrosinase)IBA
10/2021
1Granzymes (Granzyme)IBA
06/2021
1Proteins (Proteins, Gene)FDA Link
06/2021
1ASP2151IBA
04/2020
1Antiviral Agents (Antivirals)IBA
04/2020
1DNA Primase (Primase)IBA
04/2020
1ChloridesIBA
02/2020
1Chemotactic FactorsIBA
02/2020
1Anti-Bacterial Agents (Antibiotics)IBA
06/2017
1Serine Proteases (Serine Protease)IBA
01/2017
1Pharmaceutical PreparationsIBA
08/2016
1Benzoyl PeroxideFDA LinkGeneric
06/2016
1Immunoglobulin E (IgE)IBA
01/2016
1Irritants (Vesicants)IBA
04/2015
1ezogabine (retigabine)IBA
02/2014
1Analgesics (Analgesic Drugs)IBA
02/2014
1Anticonvulsants (Antiepileptic Drugs)IBA
02/2014
1Freund's AdjuvantIBA
02/2014
1Toll-Like Receptor 4IBA
10/2010
1CC ChemokinesIBA
01/2007
1Epoxide HydrolasesIBA
01/2007
1Interleukin-1beta (Interleukin 1 beta)IBA
01/2007
1EnzymesIBA
01/2007
1CatalaseIBA
01/2007
1Interleukin-8 (Interleukin 8)IBA
01/2007
1AntioxidantsIBA
01/2007
1Oxidants (Oxidizing Agents)IBA
01/2007
1XenobioticsIBA
01/2007
1TransferasesIBA
01/2007
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
01/2007
1Tissue Inhibitor of Metalloproteinase-2IBA
01/2007

Therapy/Procedure

1Oral Administration
02/2014